Brian Kirmse1,2, Charlotte Hobbs2,3, Lisa Aaron4, Grace Montepiedra4, Marshall Summar1, Paige L Williams4, Caitlin J Smith5, Russell Van Dyke6, Chunli Yu7, Kelli K Ryckman5, William Borkowsky3. 1. From the Division of Genetics & Metabolism, Children's National Health System, Washington, DC. 2. Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS. 3. Division of Pediatric Infectious Disease and Immunology, New York University/Langone School of Medicine, New York. 4. Harvard TH Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA. 5. Department of Epidemiology, University of Iowa, College of Public Health, Iowa City, IA. 6. Tulane University School of Medicine, New Orleans, LA. 7. Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine, Laboratory of Biochemical Genetics, New York, NY.
Abstract
BACKGROUND: Mitochondrial toxicity resulting in myopathy and lactic acidosis has been described in antiretroviral (ARV)-exposed patients. We hypothesized that myopathy in HIV-infected, ARV-treated children would be associated with metabolic (acylcarnitines) and genetic (variants in metabolic genes) markers of dysfunctional fatty acid oxidation (FAO). METHODS: Acylcarnitine profiles (ACP) were analyzed for 74 HIV-infected children on nucleoside reverse transcriptase inhibitor (NRTI)-containing ARV. Thirty-seven participants with ≥2 creatine kinase measurements >500 IU (n = 18) or evidence of echocardiographic cardiomyopathy (n = 19) were matched with 37 participants without myopathy. Single nucleotide polymorphisms (SNPs) in FAO genes were also evaluated. RESULTS: Abnormal ACP was 73% (95% CI: 56%-86%) and 62% (95% CI: 45%-78%) in the myopathic and nonmyopathic groups, respectively. No significant association was found between myopathy and having an abnormal ACP (OR = 2.10, P = 0.22). In univariate analysis, a 1-year increase in NRTI use was associated with a 20% increase in odds of at least 1 ACP abnormality [OR (95% CI) = 1.20 (1.03-1.41); P = 0.02), and a 1-year increase in protease inhibitor use was associated with 28% increase in the odds of having at least 1 ACP abnormality [OR (95% CI) = 1.28 (1.07-1.52); P = 0.006). Three SNPs, all in the gene for the carnitine transporter ( SLC22A5 ), were associated with the cardiomyopathy phenotype. CONCLUSION: FAO appears to be altered in HIV-infected children with and without myopathy, but abnormal FAO does not fully explain myopathy in ARV-exposed children. Further study of SLC22A5 variation in ARV-exposed people is warranted carnitine transporter dysfunction-related cardiomyopathy may be treatable.
BACKGROUND: Mitochondrial toxicity resulting in myopathy and lactic acidosis has been described in antiretroviral (ARV)-exposed patients. We hypothesized that myopathy in HIV-infected, ARV-treated children would be associated with metabolic (acylcarnitines) and genetic (variants in metabolic genes) markers of dysfunctional fatty acid oxidation (FAO). METHODS: Acylcarnitine profiles (ACP) were analyzed for 74 HIV-infected children on nucleoside reverse transcriptase inhibitor (NRTI)-containing ARV. Thirty-seven participants with ≥2 creatine kinase measurements >500 IU (n = 18) or evidence of echocardiographic cardiomyopathy (n = 19) were matched with 37 participants without myopathy. Single nucleotide polymorphisms (SNPs) in FAO genes were also evaluated. RESULTS: Abnormal ACP was 73% (95% CI: 56%-86%) and 62% (95% CI: 45%-78%) in the myopathic and nonmyopathic groups, respectively. No significant association was found between myopathy and having an abnormal ACP (OR = 2.10, P = 0.22). In univariate analysis, a 1-year increase in NRTI use was associated with a 20% increase in odds of at least 1 ACP abnormality [OR (95% CI) = 1.20 (1.03-1.41); P = 0.02), and a 1-year increase in protease inhibitor use was associated with 28% increase in the odds of having at least 1 ACP abnormality [OR (95% CI) = 1.28 (1.07-1.52); P = 0.006). Three SNPs, all in the gene for the carnitine transporter ( SLC22A5 ), were associated with the cardiomyopathy phenotype. CONCLUSION: FAO appears to be altered in HIV-infected children with and without myopathy, but abnormal FAO does not fully explain myopathy in ARV-exposed children. Further study of SLC22A5 variation in ARV-exposed people is warranted carnitine transporter dysfunction-related cardiomyopathy may be treatable.
Authors: So-Youn Shin; Ann-Kristin Petersen; Nicole Soranzo; Christian Gieger; Karsten Suhre; Robert P Mohney; David Meredith; Brigitte Wägele; Elisabeth Altmaier; Panos Deloukas; Jeanette Erdmann; Elin Grundberg; Christopher J Hammond; Martin Hrabé de Angelis; Gabi Kastenmüller; Anna Köttgen; Florian Kronenberg; Massimo Mangino; Christa Meisinger; Thomas Meitinger; Hans-Werner Mewes; Michael V Milburn; Cornelia Prehn; Johannes Raffler; Janina S Ried; Werner Römisch-Margl; Nilesh J Samani; Kerrin S Small; H-Erich Wichmann; Guangju Zhai; Thomas Illig; Tim D Spector; Jerzy Adamski Journal: Nature Date: 2011-08-31 Impact factor: 49.962
Authors: Svati H Shah; Jie-Lena Sun; Robert D Stevens; James R Bain; Michael J Muehlbauer; Karen S Pieper; Carol Haynes; Elizabeth R Hauser; William E Kraus; Christopher B Granger; Christopher B Newgard; Robert M Califf; L Kristin Newby Journal: Am Heart J Date: 2012-05 Impact factor: 4.749
Authors: Mustafa A Noor; Rex A Parker; Edward O'Mara; Dennis M Grasela; Alexander Currie; Sally L Hodder; Fred T Fiedorek; David W Haas Journal: AIDS Date: 2004-11-05 Impact factor: 4.177
Authors: Sean H Adams; Charles L Hoppel; Kerry H Lok; Ling Zhao; Scott W Wong; Paul E Minkler; Daniel H Hwang; John W Newman; W Timothy Garvey Journal: J Nutr Date: 2009-04-15 Impact factor: 4.798
Authors: Brian Kirmse; Tzy-Jyun Yao; Sean Hofherr; Deborah Kacanek; Paige L Williams; Charlotte V Hobbs; Rohan Hazra; William Borkowsky; Russell B Van Dyke; Marshall Summar Journal: AIDS Res Hum Retroviruses Date: 2016-01-19 Impact factor: 2.205